Harbor Transformative Technologies ETF (TEC) returned -8.80% in Q1 2026, trailing its Nasdaq-100 benchmark. Read the full ...
Delgocitinib tripled week-16 treatment success versus placebo (RR 3.17), yielding an absolute 16.9% benefit and NNT of 6. Early separation by week 4 supports adherence, with sustained superiority at ...
Rheinmetall AG upgraded to Strong Buy after a headline-driven dip; NATO defense spending cycle supports demand. Click for an ...
Morning Overview on MSN
7 SUVs built to cruise past 300,000 miles without a major repair
Buyers shopping for a used SUV face a stark reality: average repair costs for vehicles past 100,000 miles have climbed ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results